EcoDrugPlus

Group 10 Secretory Phospholipase A2-Like

Ensembl ID : ENSHCOG00000006605
Gene Symbol: LOC109513802
3 Cross references
232 Possible Orthologues:

Growth Hormone Releasing Hormone Receptor

Ensembl ID : ENSHCOG00000018993
Gene Symbol: GHRHR
4 Cross references
191 Possible Orthologues:

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSHCOG00000014645
Gene Symbol: GHSR
3 Cross references
212 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSHCOG00000020026
Gene Symbol: GUCY1A1
3 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSHCOG00000015363
Gene Symbol: GUCY1A2
4 Cross references
202 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSHCOG00000019727
Gene Symbol: GUCY1B1
3 Cross references
210 Possible Orthologues:

Heat Shock Protein 90 Alpha Family Class A Member 1

Ensembl ID : ENSHCOG00000014636
Gene Symbol: HSP90AA1
4 Cross references
287 Possible Orthologues:

Heat Shock Protein 90 Alpha Family Class B Member 1

Ensembl ID : ENSHCOG00000005230
Gene Symbol: HSP90AB1
3 Cross references
82 Possible Orthologues:

Heat Shock Protein Hsp 90-Alpha 1

Ensembl ID : ENSHCOG00000014614
Gene Symbol: LOC109531013
3 Cross references
327 Possible Orthologues:

High Mobility Group Protein B1-Like

Ensembl ID : ENSHCOG00000012462
Gene Symbol: LOC109517338
2 Cross references
511 Possible Orthologues:

High Mobility Group Protein B1-Like

Ensembl ID : ENSHCOG00000011037
Gene Symbol: LOC109507844
3 Cross references
509 Possible Orthologues:

Histamine H2 Receptor-Like

Ensembl ID : ENSHCOG00000010815
Gene Symbol: LOC109524349
3 Cross references
189 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).